---
title: Early detection slows Parkinson progression
nct_id: NCT07467460
status: RECRUITING
sponsor: Neuromed IRCCS
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07467460"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07467460"
last_fetched: "2026-05-10T14:06:35.616Z"
source: "Parkinson's Pathways (curated)"
---
# Early detection slows Parkinson progression

**Goal (in five words):** Early detection slows Parkinson progression

**Official Title:** NEUROTECHNO: Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.

**Trial ID:** [NCT07467460](https://clinicaltrials.gov/study/NCT07467460)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Neuromed IRCCS
- **Target Enrollment:** 500 participants
- **Start Date:** 2026-02-17
- **Completion Date:** 2028-09-30
- **Conditions:** PARKINSON DISEASE (Disorder), Alzheimer s Disease, Diabete Type 2

## Summary For Families

Aiming to build precision medicine tools that improve diagnosis and personalize care for Parkinson's and Alzheimer's by linking clinical features with biological markers. The project is observational, collecting clinical exams, imaging and biomarkers like amyloid PET and cerebrospinal fluid measures, plus detailed medication-response data for Parkinson's, for example documented responses to L‑dopa, which is converted to dopamine to replace the brain's lost dopamine, and to dopamine agonists, so researchers can predict who will benefit from specific therapies. Recruiting about 500 adults 18 and older, it is looking for people with Parkinson's who have at least two cardinal signs including tremor or bradykinesia and no atypical features, or people with probable Alzheimer's confirmed by amyloid biomarkers; people with pre-existing psychiatric disorders, other neurodegenerative diseases, or dementia are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* -Inclusion Criteria:
* Inclusion criteria for PD patients. For the IRCCS INM Neuromed, patients will be recruited from those affiliated with the Center for the Study and Treatment of Parkinson's Disease of the Neuromed Institute of Pozzilli.

Presence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, asymmetric onset), one of which must be tremor or bradykinesia:

Absence of atypical symptoms such as: i) early postural instability, freezing episodes, cognitive decline, hallucinations, pathological involuntary movements, vertical gaze palsy; ii) confirmed causes of secondary parkinsonism (focal lesions, medications, toxic substances); Documented response to L-dopa or dopamine agonists (or lack of an adequate therapeutic trial with L-dopa or dopamine agonists).

-Inclusion criteria forAD patients. For the University of Campania, patients will be selected at the Department of Advanced Medical and Surgical Sciences of the University of Campania "L. Vanvitelli," located at Piazza Miraglia 2, Naples. The Department will establish a collaboration with the Alzheimer's day centers of ASL NA1 (Geriatric Facility "Villa Walpole" - Via Ponti Rossi, 118 - Naples, and Geriatric Facility "Frullone" - Via Comunale del Principe, 16/A - Naples) to identify potential subjects for screening to verify the parameters required for recruitment. The Geriatrics and Internal Medicine Unit (UOC), AOU University of Campania, will also be involved.

Patients with AD will be included following a diagnosis of probable Alzheimer's disease according to the McKhann criteria (2011), supported by positive biomarkers for amyloidopathy (amyloid PET or cerebrospinal fluid amyloid assay).

Exclusion Criteria:

* Pre-existing psychiatric disorders;
* Neurodegenerative neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, neuromuscular disorders, epilepsy;
* Diagnosis of dementia.
```

## Locations (1)

- IRCCS INM Neuromed, Pozzilli, Italy _(41.5114, 14.0625)_
  - Teresa Esposito, PhD — (CONTACT) — +30 0865915249 — teresa.esposito@igb.cnr.it

## Central Contacts

- Teresa Esposito, PhD — (CONTACT) — +39 0865915249 — teresa.esposito@igb.cnr.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT07467460*  
*HTML version: https://parkinsonspathways.com/trial/NCT07467460*  
*Source data: https://clinicaltrials.gov/study/NCT07467460*